IBDEI0AO ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14245,0)
 ;;=286.6^^87^775^13
 ;;^UTILITY(U,$J,358.3,14245,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14245,1,1,0)
 ;;=1^286.6
 ;;^UTILITY(U,$J,358.3,14245,1,8,0)
 ;;=8^Defibrination Syndrome
 ;;^UTILITY(U,$J,358.3,14245,2)
 ;;=^35673
 ;;^UTILITY(U,$J,358.3,14246,0)
 ;;=286.7^^87^775^1
 ;;^UTILITY(U,$J,358.3,14246,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14246,1,1,0)
 ;;=1^286.7
 ;;^UTILITY(U,$J,358.3,14246,1,8,0)
 ;;=8^Acquired Coagulation Factor Def
 ;;^UTILITY(U,$J,358.3,14246,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,14247,0)
 ;;=286.9^^87^775^12
 ;;^UTILITY(U,$J,358.3,14247,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14247,1,1,0)
 ;;=1^286.9
 ;;^UTILITY(U,$J,358.3,14247,1,8,0)
 ;;=8^Defective Coagulation,Unspec
 ;;^UTILITY(U,$J,358.3,14247,2)
 ;;=^87267
 ;;^UTILITY(U,$J,358.3,14248,0)
 ;;=287.0^^87^775^4
 ;;^UTILITY(U,$J,358.3,14248,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14248,1,1,0)
 ;;=1^287.0
 ;;^UTILITY(U,$J,358.3,14248,1,8,0)
 ;;=8^Allergic Purpura
 ;;^UTILITY(U,$J,358.3,14248,2)
 ;;=^101365
 ;;^UTILITY(U,$J,358.3,14249,0)
 ;;=287.1^^87^775^24
 ;;^UTILITY(U,$J,358.3,14249,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14249,1,1,0)
 ;;=1^287.1
 ;;^UTILITY(U,$J,358.3,14249,1,8,0)
 ;;=8^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,14249,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,14250,0)
 ;;=287.2^^87^775^18
 ;;^UTILITY(U,$J,358.3,14250,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14250,1,1,0)
 ;;=1^287.2
 ;;^UTILITY(U,$J,358.3,14250,1,8,0)
 ;;=8^Oth Nonthrombocytopenic Purpuras
 ;;^UTILITY(U,$J,358.3,14250,2)
 ;;=^87741
 ;;^UTILITY(U,$J,358.3,14251,0)
 ;;=287.31^^87^775^15
 ;;^UTILITY(U,$J,358.3,14251,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14251,1,1,0)
 ;;=1^287.31
 ;;^UTILITY(U,$J,358.3,14251,1,8,0)
 ;;=8^Immune Thrombocytopenic Purpura
 ;;^UTILITY(U,$J,358.3,14251,2)
 ;;=^332746
 ;;^UTILITY(U,$J,358.3,14252,0)
 ;;=287.32^^87^775^14
 ;;^UTILITY(U,$J,358.3,14252,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14252,1,1,0)
 ;;=1^287.32
 ;;^UTILITY(U,$J,358.3,14252,1,8,0)
 ;;=8^Evan's Syndrome
 ;;^UTILITY(U,$J,358.3,14252,2)
 ;;=^332747
 ;;^UTILITY(U,$J,358.3,14253,0)
 ;;=287.41^^87^775^21
 ;;^UTILITY(U,$J,358.3,14253,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14253,1,1,0)
 ;;=1^287.41
 ;;^UTILITY(U,$J,358.3,14253,1,8,0)
 ;;=8^Posttransfusion Purpura
 ;;^UTILITY(U,$J,358.3,14253,2)
 ;;=^339609
 ;;^UTILITY(U,$J,358.3,14254,0)
 ;;=287.49^^87^775^19
 ;;^UTILITY(U,$J,358.3,14254,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14254,1,1,0)
 ;;=1^287.49
 ;;^UTILITY(U,$J,358.3,14254,1,8,0)
 ;;=8^Oth Secondary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,14254,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,14255,0)
 ;;=287.8^^87^775^20
 ;;^UTILITY(U,$J,358.3,14255,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14255,1,1,0)
 ;;=1^287.8
 ;;^UTILITY(U,$J,358.3,14255,1,8,0)
 ;;=8^Oth Spec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,14255,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,14256,0)
 ;;=287.9^^87^775^29
 ;;^UTILITY(U,$J,358.3,14256,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14256,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,14256,1,8,0)
 ;;=8^Unspec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,14256,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,14257,0)
 ;;=205.00^^87^776^32
 ;;^UTILITY(U,$J,358.3,14257,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14257,1,1,0)
 ;;=1^205.00
 ;;^UTILITY(U,$J,358.3,14257,1,8,0)
 ;;=8^Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,14257,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,14258,0)
 ;;=205.01^^87^776^31
 ;;^UTILITY(U,$J,358.3,14258,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14258,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,14258,1,8,0)
 ;;=8^Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,14258,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,14259,0)
 ;;=205.10^^87^776^18
 ;;^UTILITY(U,$J,358.3,14259,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14259,1,1,0)
 ;;=1^205.10
 ;;^UTILITY(U,$J,358.3,14259,1,8,0)
 ;;=8^Chr Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,14259,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,14260,0)
 ;;=205.11^^87^776^17
 ;;^UTILITY(U,$J,358.3,14260,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14260,1,1,0)
 ;;=1^205.11
 ;;^UTILITY(U,$J,358.3,14260,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,14260,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,14261,0)
 ;;=289.0^^87^776^50
 ;;^UTILITY(U,$J,358.3,14261,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14261,1,1,0)
 ;;=1^289.0
 ;;^UTILITY(U,$J,358.3,14261,1,8,0)
 ;;=8^Secondary Polycythemia
 ;;^UTILITY(U,$J,358.3,14261,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,14262,0)
 ;;=238.4^^87^776^48
 ;;^UTILITY(U,$J,358.3,14262,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14262,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,14262,1,8,0)
 ;;=8^Polycythemia Rubra Vera
 ;;^UTILITY(U,$J,358.3,14262,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,14263,0)
 ;;=288.9^^87^776^67
 ;;^UTILITY(U,$J,358.3,14263,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14263,1,1,0)
 ;;=1^288.9
 ;;^UTILITY(U,$J,358.3,14263,1,8,0)
 ;;=8^Unspecified Dis Of W B C
 ;;^UTILITY(U,$J,358.3,14263,2)
 ;;=^267993
 ;;^UTILITY(U,$J,358.3,14264,0)
 ;;=289.81^^87^776^49
 ;;^UTILITY(U,$J,358.3,14264,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14264,1,1,0)
 ;;=1^289.81
 ;;^UTILITY(U,$J,358.3,14264,1,8,0)
 ;;=8^Primary Hypercoagulable State
 ;;^UTILITY(U,$J,358.3,14264,2)
 ;;=^329886
 ;;^UTILITY(U,$J,358.3,14265,0)
 ;;=238.75^^87^776^29
 ;;^UTILITY(U,$J,358.3,14265,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14265,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,14265,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,14265,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,14266,0)
 ;;=289.9^^87^776^66
 ;;^UTILITY(U,$J,358.3,14266,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14266,1,1,0)
 ;;=1^289.9
 ;;^UTILITY(U,$J,358.3,14266,1,8,0)
 ;;=8^Unspecified Blood Disease
 ;;^UTILITY(U,$J,358.3,14266,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,14267,0)
 ;;=205.02^^87^776^30
 ;;^UTILITY(U,$J,358.3,14267,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14267,1,1,0)
 ;;=1^205.02
 ;;^UTILITY(U,$J,358.3,14267,1,8,0)
 ;;=8^Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,14267,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,14268,0)
 ;;=205.12^^87^776^16
 ;;^UTILITY(U,$J,358.3,14268,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14268,1,1,0)
 ;;=1^205.12
 ;;^UTILITY(U,$J,358.3,14268,1,8,0)
 ;;=8^Chr Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,14268,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,14269,0)
 ;;=205.20^^87^776^59
 ;;^UTILITY(U,$J,358.3,14269,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14269,1,1,0)
 ;;=1^205.20
 ;;^UTILITY(U,$J,358.3,14269,1,8,0)
 ;;=8^Subacute Myeloid Leuk w/o Remiss
 ;;^UTILITY(U,$J,358.3,14269,2)
 ;;=^336857
 ;;^UTILITY(U,$J,358.3,14270,0)
 ;;=205.21^^87^776^58
 ;;^UTILITY(U,$J,358.3,14270,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14270,1,1,0)
 ;;=1^205.21
 ;;^UTILITY(U,$J,358.3,14270,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Remiss
 ;;^UTILITY(U,$J,358.3,14270,2)
 ;;=^267536
 ;;^UTILITY(U,$J,358.3,14271,0)
 ;;=205.22^^87^776^57
 ;;^UTILITY(U,$J,358.3,14271,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14271,1,1,0)
 ;;=1^205.22
 ;;^UTILITY(U,$J,358.3,14271,1,8,0)
 ;;=8^Subacute Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,14271,2)
 ;;=^336472
 ;;^UTILITY(U,$J,358.3,14272,0)
 ;;=205.30^^87^776^35
 ;;^UTILITY(U,$J,358.3,14272,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14272,1,1,0)
 ;;=1^205.30
 ;;^UTILITY(U,$J,358.3,14272,1,8,0)
 ;;=8^Myeloid Sarcoma w/o Remission
 ;;^UTILITY(U,$J,358.3,14272,2)
 ;;=^336858
 ;;^UTILITY(U,$J,358.3,14273,0)
 ;;=205.31^^87^776^34
 ;;^UTILITY(U,$J,358.3,14273,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14273,1,1,0)
 ;;=1^205.31
 ;;^UTILITY(U,$J,358.3,14273,1,8,0)
 ;;=8^Myeloid Sarcoma in Remission
 ;;^UTILITY(U,$J,358.3,14273,2)
 ;;=^267538
 ;;^UTILITY(U,$J,358.3,14274,0)
 ;;=205.32^^87^776^33
 ;;^UTILITY(U,$J,358.3,14274,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14274,1,1,0)
 ;;=1^205.32
 ;;^UTILITY(U,$J,358.3,14274,1,8,0)
 ;;=8^Myeloid Sarcoma in Relapse
 ;;^UTILITY(U,$J,358.3,14274,2)
 ;;=^336473
 ;;^UTILITY(U,$J,358.3,14275,0)
 ;;=205.80^^87^776^44
 ;;^UTILITY(U,$J,358.3,14275,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14275,1,1,0)
 ;;=1^205.80
 ;;^UTILITY(U,$J,358.3,14275,1,8,0)
 ;;=8^Oth Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,14275,2)
 ;;=^336859
 ;;^UTILITY(U,$J,358.3,14276,0)
 ;;=205.81^^87^776^43
 ;;^UTILITY(U,$J,358.3,14276,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14276,1,1,0)
 ;;=1^205.81
 ;;^UTILITY(U,$J,358.3,14276,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Remission
 ;;^UTILITY(U,$J,358.3,14276,2)
 ;;=^267540
 ;;^UTILITY(U,$J,358.3,14277,0)
 ;;=205.82^^87^776^42
 ;;^UTILITY(U,$J,358.3,14277,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14277,1,1,0)
 ;;=1^205.82
 ;;^UTILITY(U,$J,358.3,14277,1,8,0)
 ;;=8^Oth Myeloid Leukemia in Relapse
 ;;^UTILITY(U,$J,358.3,14277,2)
 ;;=^336474
 ;;^UTILITY(U,$J,358.3,14278,0)
 ;;=205.90^^87^776^65
 ;;^UTILITY(U,$J,358.3,14278,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14278,1,1,0)
 ;;=1^205.90
 ;;^UTILITY(U,$J,358.3,14278,1,8,0)
 ;;=8^Unspec Myeloid Leuk w/o Remission
 ;;^UTILITY(U,$J,358.3,14278,2)
 ;;=^336860
 ;;^UTILITY(U,$J,358.3,14279,0)
 ;;=205.91^^87^776^64
 ;;^UTILITY(U,$J,358.3,14279,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14279,1,1,0)
 ;;=1^205.91
 ;;^UTILITY(U,$J,358.3,14279,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Remission
 ;;^UTILITY(U,$J,358.3,14279,2)
 ;;=^267542
 ;;^UTILITY(U,$J,358.3,14280,0)
 ;;=205.92^^87^776^63
 ;;^UTILITY(U,$J,358.3,14280,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,14280,1,1,0)
 ;;=1^205.92
 ;;^UTILITY(U,$J,358.3,14280,1,8,0)
 ;;=8^Unspec Myeloid Leuk in Relapse
 ;;^UTILITY(U,$J,358.3,14280,2)
 ;;=^336475
 ;;^UTILITY(U,$J,358.3,14281,0)
 ;;=206.00^^87^776^6
 ;;^UTILITY(U,$J,358.3,14281,1,0)
 ;;=^358.31IA^8^2
